Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone,quetiapine or olanzapine in general practice in England including patients with dementia

Abstract

Following changes in the safety information on the use of risperidone and olanzapine in elderly patients with dementia, data from prescription-event monitoring (PEM) studies of risperidone, quetiapine and olanzapine were examined. The aim was to compare incidence rates for events reported as cerebrovascular accident (CVA) and transient ischaemic attack (TIA) during the first 180 days of treatment in patients prescribed atypical antipsychotics for dementia or other indications, because of the possible association between dementia and stroke in users of atypical antipsychotics. A retrospective analysis of data from the three observational studies was conducted using Poisson regression modelling and survival analysis. Within the risperidone, quetiapine and olanzapine cohorts, 23 (0.30%), 6 (0.35%) and 10 (0.11%) patients respectively, were reported to have had a CVA/TIA event. Age, sex and indication (dementia or other) were identified as important confounding variables; age being the most important. The crude rate ratios (RRs) for CVA/TIA for risperidone or quetiapine vs. olanzapine indicated an approximate threefold relative difference in rate during the first six months but after adjustment for age, sex and indication, the RRs were non-significant (1.2 (95% CI 0.5,3.0) and 2.1 (95% CI 0.6,7.7), respectively). For risperidone vs. quetiapine, crude and adjusted RRs were not significantly different. Of the three drugs, the time to event was shortest for risperidone and also shortest for risperidone or quetiapine users where the indication was dementia. The age and sex adjusted RR of CVA/TIA in patients prescribed risperidone for dementia vs. other indications was 6.7 (95% CI 2.4,18.9). The adjusted RRs for quetiapine, according to indication, could not be calculated due to missing information on age and sex. There were no cases of CVA/TIA with dementia for olanzapine, thus the RRs and time to event curves according to indication could not be examined. This study revealed no significant difference in the adjusted RR of CVA/TIA events in the first 180 days of treatment in patients prescribed risperidone or quetiapine when compared with olanzapine. However, dementia appears to be an important risk factor. These results should be considered alongside other pharmacoepidemiological studies on this topic.

Keywords

cerebrovascular accidents transient ischaemic attacks risperidone olanzapine quetiapine atypical antipsychotics dementia observational cohort studies prescription-event monitoring

Get full access to this article

View all access options for this article.

References

Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106

Bhana N , Spencer C M (2000) Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging 16: 451-471

Committee on Safety of Medicine, London, DoH (2004) Atypical antipsychotic drugs and stroke. Web address: http://www.mhra.gov.uk/news/antipsystroke_9304.htm.Date accessed 9/3/2004

Dear Healthcare Professional (2002) Risperdal* (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials. Janssen-Ortho, Canada

Dear Healthcare Professional (2004a) The risk of cerebrovascular adverse events (CVAE) in elderly patients with dementia: important changes to the summary of product characteristics relating to use of risperidone. Janssen-Cilag Ltd, High Wycombe

Dear Healthcare Professional (2004b) Zyprexa*(olanzapine) and cerebrovascular adverse events in placebo-controlled elderly dementia trials. Eli Lilly Canada Inc, Canada

Dear Healthcare Professional (2004c) Important safety information on olanzepine and risk of mortality and stroke in elderly patients with dementia-related psychosis and/or behavioural disturbances. Eli Lilly and Company Ltd, Basingstoke

Douglas-Hall P , Fuller A , Gill-Banham S . (2001) An analysis of offlicence prescribing in psychiatric medicine. Pharmaceutical Journal 267: 890-891

Eli Lilly and Company Limited (2004) Summary of product characteristics Zyprexa (olanzapine). Eli Lilly and Company Ltd

10.

Faculty of the Psychiatry of Old Age (2005) Prescribing update for old age psychiatrists. Website address: www.rcpsych.ac.uk/college/faculty/oap/BPSD.pdf. Date accessed 05/04/2005

11.

Haddad P M , Anderson I M (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62: 1649-1671

12.

Herrmann N , Mamdani M , Lanctot K L . (2004) Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 161: 1113-1115

13.

Irish Medicines Board (2004) IMB stresses Important New Safety Information on Olanzapine

14.

Janssen-Cilag Ltd (2004) Summary of product characteristics Risperdal (risperidone). Janssen-Cilag Ltd

15.

Kirchner V , Kelly CA , Harvey R J . (2004) Thioridazine for dementia (Cochrane Review). John Wiley & Sons Ltd, Chichester

16.

Layton D , Heeley E , Hughes K , Shakir SA (2003) Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology (Oxford) 42: 622-631

17.

Lee P E , Gill S S , Freedman M , Bronskill S E , Hillmer M P , Rochan P A . (2004) Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 329: 75

18.

Lowe-Ponsford F , Baldwin D (2000) Off-label prescribing by psychiatrists. Psychiatric Bulletin 24: 415-417

19.

Machin D , Campbell M , Fayers P , Pinol A P Y . (1997a) Sample Size Tables for Clinical Studies. Table 7.1. Blackwell Science Ltd, Oxford

20.

Machin D , Campbell M , Fayers P , Pinol A P Y (1997b) Sample Size Tables for Clinical Studies. Table 7.2. Blackwell Science Ltd, Oxford

21.

Mann R D , Rawlins M D , Fletcher P (1992) Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Saf 1: 19-23

22.

Medsafe (2003) Risperidone and cerebrovascular accidents in elderly patients with dementia. Web address: http://www.medsafe.govt.nz. Date accessed 9/3/2004

23.

Medwatch (2003) The FDA Safety Information and Adverse Event Reporting Program 2003 Safety Alert Risperdal (risperidone). Dear healthcare professional letter. Web address: http://www.fda.gov/medwatch/SAFETY2005/risperdal.htm. Date accessed 02/12/2003.

24.

National Institute of Clinical Excellence (2002) Guidance on the use of newer (atypical) antipsychotic agents for the treatment of schizophrenia. NICE, London

25.

Oborne C A , Hooper R , Swift C G , Jackson S H . (2002) An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing 31: 435-439

26.

Rasanen S , Hakko H , Villo K , Meyer-Rochow V B , Moring J . (2003) Excess mortality among long-stay psychiatric patients in northern Finland. Soc Psychiatry Psychiatr Epidemiol 38: 297-304

27.

Schmidt R , Schmidt H , Fazekas F . (2000) Vascular risk factors in dementia. J Neurol 247: 81-87

28.

Schneider L S , Tariot P N , Lyketsos C G , Dugerman K S , Davis K L , Davis S , Hsiao J K , Veste D V , Katz I R , Olin J T , Pollock B G , Rabins P V , Rosenheck R A , Small G W , Lebowitz B , Lieberman J A . (2001) National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. American Journal of Geriatric Psychiatry 9: 346-360

29.

Shakir S A (2002) PEM in the UK. In Mann R D , Andrews E (eds), Pharmacovigilance. John Wiley & Sons Ltd, Chichester, pp. 333-344

30.

Sink K M , Holden K F , Yaffe K . (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293: 596-608

31.

Strom B (1994) Sample size considerations for pharmacoepidemiology studies. In Strom B (ed.), Pharmacoepidemiology. John Wiley & Sons, Chichester

32.

The European Agency for the Evaluation of Medicinal Products (2004) Public statement on the safety of olanzapine (Zyprexa zyprexa vclotab). Ref EMEA/CPMP/856/04/Final. London.

33.

West S , Strom B L et al. (2002) Validity of pharmacoepidemiology drug and diagnosis data. In Strom B L (ed.), Pharmacoepidemiology. John Wiley & Sons Ltd, Chichester, pp. 661-705

34.

Wooltorton E (2002) Practice Health Drug Alerts. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 167: 1269-1270